UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Netflix Stock Drops After Weak Q3 Outlook Overshadows Mixed Q2 Earnings 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Trump Criticizes ABC, NBC and CNN for Limiting Coverage of Election Speech 
GameStop Raises eBay Stake to 9.8% as Ryan Cohen Pushes $56 Billion Takeover Bid 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Moonshot Launches Kimi K3, China's Largest Open-Source AI Model 
DeepSeek Eyes $74 Billion Valuation Ahead of Planned China IPO 
Seven & i Eyes Żabka Stake in Major European Expansion Push 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Illumina, Inc., a San Diego, California-headquartered biotechnology firm, announced that its chief financial officer, Joydeep Goswani, is leaving. His departure was confirmed on Tuesday, April 9.
New Executives at the HQ
The company said it has appointed Ankur Dhingra as its new CFO. Goswani's successor is revealed to be an executive at Summit Therapeutics. He will be leaving the company, where he most recently served in the same chief financial role, to join Illumina.
Aside from Dhingra, Illumina is also welcoming Jakob Wedel, who has been named the new chief strategy and corporate development officer. At any rate, Reuters reported that the new CFO worked at CareDx, a medical test manufacturer, before being hired at Summit Therapeutics. He also spent almost 18 years at Agilent Technologies and has decades of experience in the life science business sector.
Relocation and Date of Leadership Appointments
Meanwhile, Illumina's newly appointed senior executives, Dhingra and Wedel, are set to be transferred to San Diego for their respective roles. The two will start working at the company on April 15. On the other hand, Goswami will remain in the company until June 30 and officially leave on July 1.
"I am proud of the talent joining our management team as we work to deliver on Illumina's mission to improve human health by unlocking the power of the genome," Illumina's chief executive officer, Jacob Thaysen, said in a press release. "Ankur brings deep financial expertise, investor and leadership experience, and industry knowledge to Illumina's CFO role, and Jakob has keen insights gained from 25 years in strategy leadership roles with global consulting firms."
The CEO added, "We are grateful to Joydeep for his many contributions to Illumina over more than four years, and for most recently leading these two key functions. Joydeep will continue with us for several weeks to support a smooth leadership transition."
Photo by: Illumina Press Release
